

Supplemental Approvals

Generic Name (Trade Name) Company

November 19, 2015

Naloxone hydrochloride nasal spray

Uses/Notes

[FDA has approved naloxone hydrochloride](#) as a nasal spray under the trade name Narcan. It is the first FDA-approved nasal spray version of naloxone, a life-saving medication that can stop or reverse the effects of an opioid overdose.

Until this approval, naloxone was only approved in [injectable forms, most commonly delivered by syringe or auto-injector](#). Many first responders and primary caregivers, however, feel a nasal spray formulation of naloxone is easier to deliver and eliminates the risk of a contaminated needle stick. As a result, there has been widespread use of unapproved naloxone kits that combine an injectable formulation of naloxone with an atomizer that can deliver naloxone nasally. Now, people have access to an FDA-approved product for which the drug and its delivery device have met the FDA's high standards for safety, efficacy and quality.

Narcan nasal spray does not require assembly and delivers a consistent, measured dose when used as directed. This prescription product can be used on adults or children and is easily administered by anyone, even those without medical training. The drug is sprayed into one nostril while the patient is lying on his or her back and can be repeated if necessary.

However, it is important to note that it is not a substitute for immediate medical care, and the person administering Narcan nasal spray should seek further immediate medical attention on the patient's behalf.

The FDA granted [fast-track](#) designation and [priority review](#) for Narcan nasal spray. Narcan is being approved in less than 4 months, significantly ahead of the product's prescription drug user fee goal date of January 20, 2016.

In clinical trials conducted to support the approval of Narcan nasal spray, administering the drug in one nostril delivered approximately the same levels or higher of naloxone as a single dose of an FDA-approved naloxone intramuscular injection, and achieved these

(Narcan—Adapt Pharma)

FDA moves quickly to approve easy-to-use nasal spray to treat opioid overdose

levels in approximately the same time frame.

The [National Institute on Drug Abuse](#) (NIDA) played a critical role in the development of Narcan nasal spray as well, forming a public–private partnership by designing and conducting the clinical trials required to determine that the intranasal formulation delivered naloxone as quickly and as effectively as an injection. NIDA then worked with its private sector partners to obtain FDA approval.

Use of Narcan nasal spray in patients who are [opioid dependent](#) may result in severe opioid withdrawal characterized by body aches, diarrhea, increased heart rate, fever, runny nose, sneezing, goose bumps, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, abdominal cramps, weakness, and increased blood pressure.

Source URL:

<http://aphanet.org/supplemental-approvals/fda-moves-quickly-approve-easy-use-nasal-spray-treat-opioid-overdose>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.